HC Wainwright set a $33.00 target price on RedHill Biopharma Ltd. (NASDAQ:RDHL) in a report released on Friday. The firm currently has a a buy rating on the stock.

RDHL has been the subject of several other reports. Zacks Investment Research upgraded shares of RedHill Biopharma from a sell rating to a hold rating in a research note on Friday, August 26th. FBR & Co lifted their price objective on shares of RedHill Biopharma from $33.00 to $36.00 and gave the stock an outperform rating in a research note on Wednesday, July 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. RedHill Biopharma has an average rating of Buy and an average price target of $26.20.

Analyst Recommendations for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ:RDHL) traded up 4.13% during midday trading on Friday, hitting $14.36. The stock had a trading volume of 16,010 shares. The firm’s market capitalization is $182.86 million. The firm has a 50-day moving average of $14.70 and a 200 day moving average of $12.76. RedHill Biopharma has a 52-week low of $8.10 and a 52-week high of $16.54.

RedHill Biopharma (NASDAQ:RDHL) last announced its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. On average, equities analysts forecast that RedHill Biopharma will post ($2.06) EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of RDHL. Royal Bank of Canada boosted its position in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of RedHill Biopharma during the second quarter valued at about $142,000. Ingalls & Snyder LLC acquired a new position in shares of RedHill Biopharma during the second quarter valued at about $451,000. Finally, Van ECK Associates Corp boosted its position in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the period. 15.30% of the stock is owned by hedge funds and other institutional investors.

About RedHill Biopharma

5 Day Chart for NASDAQ:RDHL

Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.